

Citations

1. Upton R. Hawthorn berry. American Herbal Pharmacopoeia. Santa Cruz, Calif; 1999.
2. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998:685.
3. ESCOP. Crataegi Folium cum Flore. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003.
4. Upton R. Hawthorn leaf with flower. American Herbal Pharmacopoeia. Santa Cruz, Calif; 1999.
5. WHO. Folium cum Flore Crataegi. WHO Monographs on Selected Medicinal Plants. 2 vol. Geneva: World Health Organization; 2002:66-82.
6. Ellingwood F, Lloyd J. Crataegus oxyacantha. The American Materia Medica: Therapeutics and Pharmacognosy. Eclectic Medical Publications, Portland, Ore; 1983 ed. Cincinnati; 1919:217-220.
7. Felter H. Crataegus. The Eclectic Materia Medica: Pharmacology and Therapeutics. Eclectic Medical Publications, Portland, Ore; 1985 ed. Cincinnati; 1922:325-326.
8. Weiss R. Organic heart disease, heart failure. Herbal Medicine. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988:126-149.
9. Brinker F. Herb Contraindications and Drug Interactions. 3rd ed. Sandy, Ore: Eclectic Medical Publications; 2001.
10. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003;114:665-674.
11. Leuchtgens H. [Crataegus special extract WS 1442 in NYHA II heart failure: a placebo-controlled randomized double-blind study]. Fortschr Med 1993;111:352-354.
12. Holubarsch CJ, Colucci WS, Meinertz T et al. Survival and Prognosis Investigation of Crataegus Extract WS 1442 in Congestive Heart Failure (SPICE): rationale, study design and study protocol. Eur J Heart Fail 2000;2:431-437.
13. Zick SM, Blume A, Aaronson KD. The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail 2005;11:586-589.
14. Beaufils P, Leenhardt A, Denjoy I, Slama R. Antiarrhythmic drugs in the adult population. In: Rosen M, Janse M, Wit A, eds. Cardiac Electrophysiology. Mount Kisco, NY: Futura Publishing Company Inc; 1990:1175-1192.
15. Joseph G, Zhao Y, Klaus W. [Pharmacologic action profile of Crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart]. Arzneimittelforschung 1995;45:1261-1265.
16. Iwamoto M, Sato T, Ishizaki T. [The clinical effect of Crataegutt in heart disease of ischemic or hypertensive origin: a multicenter double-blind study]. Planta Med 1981;42:1-16.
17. Muller A, Linke W, Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med 1999;65:335-339.
18. Loew D. [Phytogenic drugs in heart diseases exemplified by Crataegus]. Wien Med Wochenschr 1999;149:226-228.
19. Loew D. Phytotherapy in heart failure. Phytomedicine 1997;4:267-271.
20. Popping S, Rose H, Ionescu I et al. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995;45:1157-1161.
21. Meinertz T, Zehender M, Hohnloser SH. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study]. Z Kardiol 1992;81 Suppl 4:145-149.
22. Lucchesi BR, Chi L, Friedrichs GS et al. Antiarrhythmic versus antifibrillatory actions: inference from experimental studies. Am J Cardiol 1993;72:25F-44F.
23. Blesken R. [Crataegus in cardiology]. Fortschr Med 1992;110:290-292.
24. Schussler M, Holz J, Rump AF, Fricke U. Functional and antiischaemic effects of monoacetyl-vitexinrhannoside in different in vitro models. Gen Pharmacol 1995;26:1565-1570.
25. Nasa Y, Hashizume H, Hoque AN, Abiko Y. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung 1993;43:945-949.
26. Rajendran S, Deepalakshmi PD, Parasakthy K et al. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996;123:235-241.
27. Rogers KL, Grice ID, Griffiths LR. Inhibition of platelet aggregation and 5-HT release by extracts of Australian plants used traditionally as headache treatments. Eur J Pharm Sci 2000;9:355-363.
28. Lacaille D, Franck U, Wagner H. Search for potential angiotensin-converting enzyme (ACE) inhibitors from plants. Phytomedicine 2001;8:47-52.

Citations and Reference Literature: Hawthorn

29. Ahumada C, Saenz T, Garcia D et al. The effects of a triterpene fraction isolated from *Crataegus monogyna* Jacq. on different acute inflammation models in rats and mice: leucocyte migration and phospholipase A2 inhibition. *J Pharm Pharmacol* 1997;49:329-331.
30. Vibes J, Lasserre B, Gleye J, Declume C. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of *Crataegus oxyacantha* (hawthorn) flower heads. *Prostaglandins Leukot Essent Fatty Acids* 1994;50:173-175.
31. Chen ZY, Zhang ZS, Kwan KY et al. Endothelium-dependent relaxation induced by hawthorn extract in rat mesenteric artery. *Life Sci* 1998;63:1983-1991.
32. Andriantsitohaina R. Regulation of vascular tone by plant polyphenols: role of nitric oxide. *Gen Physiol Biophys* 1999;18 Suppl 1:3-5.
33. Fan C, Yan J, Qian Y et al. Regulation of lipoprotein lipase expression by effect of hawthorn flavonoids on peroxisome proliferator response element pathway. *J Pharmacol Sci* 2006;100:51-58.
34. Koch E. Hawthorn interaction potential [letter]. *Herbalgram* 2003;59:70-71.
35. Trunzler G, Schuler E. [Comparative studies on the effect of a *Crataegus* extract, of digitoxin, digoxin and g-strophanthin on the isolated mammalian heart]. *Arzneimittelforschung* 1962;12:198-202.
36. Schwinger RH, Pietsch M, Frank K, Brixius K. *Crataegus* special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. *J Cardiovasc Pharmacol* 2000;35:700-707.
37. Long SR, Carey RA, Crofoot KM et al. Effect of hawthorn (*Crataegus oxyacantha*) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. *Phytomedicine* 2006.
38. Tankanow R, Tamer HR, Streetman DS et al. Interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*). *J Clin Pharmacol* 2003;43:637-642.
39. Conseil G, Baubichon-Cortay H, Dayan G et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. *Proc Natl Acad Sci USA* 1998;95:9831-9836.
40. John A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 1999;66:338-345.
41. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). *Circulation* 1995;92:2764-2784.
42. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997;336:525-533.
43. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the Advisory Council to improve outcomes nationwide in heart failure. *Am J Cardiol* 1999;83:1A-38A.
44. Arnsdorf MF, Wasserstrom JA. A matrical approach to the basic and clinical pharmacology of antiarrhythmic drugs. *Rev Clin Basic Pharm* 1987;6:131-188.
45. Arnsdorf MF. Cardiac excitability and antiarrhythmic drugs: a different perspective. *J Clin Pharmacol* 1989;29:395-404.
46. Arnsdorf MF. Cardiac excitability, the electrophysiologic matrix and electrically induced ventricular arrhythmias: order and reproducibility in seeming electrophysiologic chaos. *J Am Coll Cardiol* 1991;17:139-142.
47. Goldberger AL. Fractal mechanisms in the electrophysiology of the heart. *IEEE Eng Med Biol Mag* 1992;11:47-52.
48. Poon CS, Merrill CK. Decrease of cardiac chaos in congestive heart failure. *Nature* 1997;389:492-495.
49. Glass L. Chaos and heart rate variability. *J Cardiovasc Electrophysiol* 1999;10:1358-1360.
50. Pikkujamsa SM, Makikallio TH, Sourander LB et al. Cardiac interbeat interval dynamics from childhood to senescence: comparison of conventional and new measures based on fractals and chaos theory. *Circulation* 1999;100:393-399.
51. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. *Ann Oncol* 2006.
52. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 1997;15:1318-1332.
53. Tauchert M. Efficacy and safety of *Crataegus* extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. *Am Heart J* 2002;143:910-915.
54. Lalukota K, Cleland JG, Ingle L et al. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. *Eur J Heart Fail* 2004;6:953-955.
55. Harkness R, Bratman S. *Mosby's Handbook of Drug-Herb and Drug-Supplement Interactions*. St Louis: Mosby; 2003.